Tumor-infiltrating lymphocytes (TILs) have shown great promise in solid tumors [2–5], but were limited in gynecologic cancer [6–8], and conventional TIL therapy involves high-intensity lymphodepleting preconditioning with chemotherapy along with high-dose IL-2 administration [6, 9], which can cause significant toxicity and is only suitable for patients with good performance [6, 10] who receive treatment in specialized clinics [11]. Here, IL2 is linked to neoplasm.